Characteristics of patients with CMML included in the trial
| Characteristic . | N . | % . |
|---|---|---|
| No. of patients | 190 | |
| Mean age (range), y | 74.3 (28-100) | |
| Sex | ||
| Male | 116 | |
| Female | 74 | |
| CMML (World Health Organization classification) | ||
| 0 | 82 | |
| 1 | 60 | |
| 2 | 48 | |
| Proliferative | 99 | |
| Dysplastic | 91 | |
| Mean no. of leukocytes (range), ×109/L | 20.8 (3.8-137.3) | |
| Mean no. of monocytes (range), ×109/L | 4.7 (0.4-29.9) | |
| Mean platelet count (range), ×109/L | 156.3 (14-996) | |
| Mean hemoglobin level (range), g/dL | 11.6 (6.8-16.8) | |
| Karyotype | ||
| Normal | 116 | |
| Abnormal | 33 | |
| Not available | 41 | |
| Main genetic alterations, positive/tested | ||
| TET2 | 124/173 | 72 |
| SRSF2 | 63/161 | 39 |
| ASXL1 | 72/173 | 42 |
| NRAS | 29/172 | 17 |
| KRAS | 24/172 | 14 |
| CBL | 15/172 | 9 |
| Characteristic . | N . | % . |
|---|---|---|
| No. of patients | 190 | |
| Mean age (range), y | 74.3 (28-100) | |
| Sex | ||
| Male | 116 | |
| Female | 74 | |
| CMML (World Health Organization classification) | ||
| 0 | 82 | |
| 1 | 60 | |
| 2 | 48 | |
| Proliferative | 99 | |
| Dysplastic | 91 | |
| Mean no. of leukocytes (range), ×109/L | 20.8 (3.8-137.3) | |
| Mean no. of monocytes (range), ×109/L | 4.7 (0.4-29.9) | |
| Mean platelet count (range), ×109/L | 156.3 (14-996) | |
| Mean hemoglobin level (range), g/dL | 11.6 (6.8-16.8) | |
| Karyotype | ||
| Normal | 116 | |
| Abnormal | 33 | |
| Not available | 41 | |
| Main genetic alterations, positive/tested | ||
| TET2 | 124/173 | 72 |
| SRSF2 | 63/161 | 39 |
| ASXL1 | 72/173 | 42 |
| NRAS | 29/172 | 17 |
| KRAS | 24/172 | 14 |
| CBL | 15/172 | 9 |
Samples from a given patient were used for several independent experiments (supplemental Table 2), and serial sampling was performed in some patients. A total of 246 samples collected from 190 patients were tested.